BioSpace News Archive

Aeglea BioTherapeutics, today announced that it has entered into an agreement to sell the global rights to pegzilarginase, an investigational treatment for the rare metabolic disease Arginase 1 Deficiency (“ARG1-D”), to Immedica Pharma AB (“Immedica”) for $15 million in upfront cash proceeds and up to $100 million in contingent milestone payments.

Nutromics has announced that its lab-on-a-patch technology has attracted the support of multiple world-class experts from leading US and Australian institutions, who now comprise its Biosensor Advisory Board.

WuXi Vaccines, a leading global vaccine CDMO (Contract Development and Manufacturing Organization), today announced the successful GMP release of its CHO cell-based drug substance (DS) manufacturing facility located in Suzhou, China.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”)today announced it has entered into a securities purchase agreement for the purchase and sale of 7,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 7,000,000 shares of common stock in a public offering at a combined offering price of $1.00 per share (or common stock equivalents in lieu thereof) and accompanying warrant.

AptarGroup, Inc. reported strong operational performance driven by continued growth of the company’s proprietary drug delivery systems and significant sequential improvement in injectables sales as Enterprise Resource Planning system implementation effects moderated.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that the Company will release its second quarter 2023 financial results on Thursday, August 3, 2023, after the close of U.S. markets.

Osivax today announced that The Lancet Infectious Diseases published results from the company’s OVX836-003 study under the title, “Immunogenicity, safety and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: randomised, double-blind placebo-controlled, Phase 2a trial.”

Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2023 before the market opens on August 8, 2023, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that Dr. Francois Lebel, M.D., an experienced biopharmaceutical industry executive, has been appointed as Senior Vice President for preclinical and clinical development of the Group.

Inozyme Pharma, Inc. announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a price of $4.80 per share, for aggregate gross proceeds of approximately $60 million, before deducting underwriting discounts and commissions and other offering expenses.